Revenue segments as reported by the company.

Pharmacy revenues

Premiums

Fees and other revenues

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Pharmacy and other service costs

Medical costs and other benefit expenses

Selling, general and administrative expenses

Amortization of acquired intangible assets

Special items

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cigna

Express Scripts is a company that provides integrated pharmacy benefit management services including network-pharmacy claims processing; home delivery pharmacy services; specialty pharmacy benefit management, through its subsidiary Accredo; benefit-design consultation; drug-utilization review; formulary management; and medical and drug data analysis services to manage drug plans for health plans, self-insured employers and government agencies (both as administrator of employee benefits and public assistance programs). Express Scripts also offers pharmacy benefit management services for workers' compensation insurance programs. The program is accredited by URAC, the nation's largest accrediting body for pharmacy benefit management companies. The company processes pharmaceutical claims for members through a network of retail pharmacies. Its own automated pharmacies dispense long-term, chronic medications-like those for diabetes or heart disease-directly to members by home delivery.

Express Scripts

The Cigna Group is a global health company, which engages in the provision of global health services. It operates through the following segments: Evernorth Health Services, Cigna Healthcare, Other Operations, and Corporate. The Evernorth Health Services segment partners with health plans, employers, governmental organizations, and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. The Cigna Healthcare segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. The Other Operations segment consists of the remainder of business operations, which includes certain ongoing businesses and exited businesses. The Corporate segment refers to net interest expense, certain litigation matters, expense associated with frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments. The company was founded in 1792 and is headquartered in Bloomfield, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cigna posts strong Q4 earnings, eyes growth in specialized services

Cigna delivered strong financial results in Q4 2022, with robust revenue growth and operational performance across key business segments.
While facing challenges such as margin pressures and potential disenrollment, Cigna is well-positioned to capitalize on growth opportunities in 2023.
Strategic partnerships, customer-focused strategies, and financial discipline underscore Cigna's commitment to sustainable growth and shareholder value creation.
Investments in innovation, care coordination, and market expansion signal a proactive approach to navigating industry dynamics and driving future success.

Cigna reports robust Q1 earnings, eyes growth amid challenges

Cigna's Q1 2023 showcased strong financials, growth in key segments, and increased outlook.
Challenges include economic softening impact and margin expectations for the year.
Opportunities lie in customer relationships, innovation, and market-specific strategies.
Overall, Cigna remains confident in delivering on its financial and growth targets.

Cigna reports robust Q2 results, eyes growth through innovation

Cigna's Q2 2023 performance was strong, with revenue growth, customer expansion, and technological advancements driving positive outcomes.
While facing challenges like disenrollment and risk adjustment payables, Cigna is leveraging strengths in technology and cross-selling for growth.
Opportunities lie in partnerships like VillageMD, continued innovation, and strategic bidding strategies for future growth.
Overall, Cigna remains confident in delivering on adjusted EPS outlook for 2023 and 2024, with a focus on innovation and growth.

Cigna surpasses Q3 expectations, eyes $28 EPS in 2024

Cigna's Q3 performance exceeded expectations, driven by strong revenue and EPS growth across key business segments.
Strategic focus on innovation, affordability, and client partnerships positions Cigna well for future growth and value creation.
Challenges in margin expectations and enrollment declines require proactive management and strategic decision-making.
Opportunities lie in continued growth projections, strategic investments, and enhancing healthcare affordability and accessibility.

Cigna reports robust Q4 performance, eyes growth amid strategic changes

Cigna Group's Q4 2023 Earnings Call highlighted strong financial performance, leadership changes, and strategic decisions. Analyst inquiries focused on growth drivers, market outlook, and internal healthcare spend management. The outlook for 2024 includes expectations of solid adjusted EPS, revenue growth, and operating cash flow.

Cigna surpasses Q1 expectations, eyes growth through AI and biosimilars

Cigna's Q1 performance exceeded expectations, driven by strong revenue and EPS figures.
Despite challenges like noncash losses and disruptions, Cigna's strategic strengths in AI, biosimilars, and value-based care position it well for growth.
Opportunities in AI-driven healthcare solutions, biosimilar expansions, and strategic M&A offer avenues for future growth.
Cigna's focus on precision care solutions and client outcomes showcases its commitment to innovation and efficiency.

Cigna (CI) posts robust Q2 results, eyes biosimilar growth

Cigna (CI) reports strong Q2 financial results driven by Evernorth Health Services and Express Scripts' innovative programs.
Focus on affordability, access, and behavioral health services propels growth in U.S. employer business.
Challenges include navigating healthcare cost pressures and ensuring fair pricing negotiations.
Opportunities lie in biosimilar growth, sustainable revenue outlook, and strategic Medicare Advantage business sale.

Cigna reports robust Q3 earnings, eyes growth opportunities in 2025

Cigna's Q3 earnings call highlighted strong financial performance, strategic focus on shareholder value, and challenges in specialty drugs and cost trends. The company is optimistic about opportunities in 2025 and remains committed to delivering shareholder value through strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CVS Health

UnitedHealth Group

CVS Health, UnitedHealth Group and Cigna sued the Federal Trade Commission, claiming the agency's case against drug middlemen over high insulin prices in the U.S. is unconstitutional.  The complaint is the latest move in a bitter legal fight between the three largest pharmacy benefit managers, or PBMs, in the U.S. and the FTC.

CVS, UnitedHealth, Cigna sue to block FTC case over insulin prices

CI reaffirms its 2024 outlook, projecting full-year adjusted EPS to be a minimum of $28.40.

Cigna Ends Humana Merger Speculation: CI Jumps 7.3% While HUM Slips

The healthcare company put merger rumors to bed.

Why Cigna Stock Popped Today

The Cigna Group confirmed “it is not pursuing a combination with Humana.”

Why Cigna Deal With Humana Made Little Sense To Begin With

Humana

Shares of Humana Inc (NYSE:HUM) are down 3.7% at $277.38 at last glance, after Cigna Group (NYSE:CI) said it was not pursuing a merger with the smaller health insurance name, and will instead prioritize share buybacks.

2 Healthcare Stocks in Focus After Merger Talks Break Down

US health insurer Cigna has made the appropriate decision to ditch plans to merge with rival Humana (NYSE:HUM), if today's market reaction is anything to go by. Rumours of the merger, which would have created a $140 billion insurance behemoth, began circulating last December, but doubts over the deal quickly followed.

Cigna rallies after Humana mega-merger called off

Investors have long appeared skeptical about a potential merger between the two health insurers.

Humana Stock Tumbles. Cigna Won't Pursue the Health Insurer.

Health insurer Cigna Group said on Monday it is not pursuing a combination with peer Humana.

Cigna says it will not pursue combination with Humana

Reaffirming Previously Provided Outlook for Full-Year 2024, and adjusted EPS growth of at least 10% in 2025 Confirming it is not Pursuing a Combination with Humana Inc. Confirming Continuing to Use Capital to Drive Shareholder Value, including Share Repurchase and Dividends BLOOMFIELD, Conn. , Nov. 11, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE: CI) officials expect to participate in meetings with investors and analysts over the next several weeks.

The Cigna Group Affirming Its Capital Priorities

Centene

Elevance Health Inc

Molina Healthcare

Several US health insurers saw notable stock price gains following the reelection of former US President Donald Trump amid an expectation of less federal scrutiny. Humana Inc. experienced the largest increase as its stock rose 10.7% from Nov. 1 through Nov. 6, increasing from $260.71 a share to $288.51 a share.

Trump Win Gives Some U.S. Health Insurers A Post-Election Bump On Wall Street

The Cigna Group's Q3 2024 results showed once again strong revenue and earnings growth. Yet, CI shares are down almost 20% from their 52-week-high. In this article, I will discuss the reasons for the once again favorable valuation of CI stock and explain why I seized what I believe to be a compelling opportunity. I will also give my opinion on the renewed speculation about a possible merger with Humana and explain why the concerns are likely unfounded.

Cigna's Impressive Q3: 4 Compelling Reasons To Buy Now

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Cigna (CI) is a Strong Value Stock

Infirmary's hospitals, facilities and doctors on Alabama's Gulf Coast are now in-network for Cigna Healthcare MA customers MOBILE, Ala. , Nov. 1, 2024 /PRNewswire/ -- Cigna Healthcare and Mobile-based Infirmary Health have reached an agreement that allows Cigna Healthcare's Medicare Advantage (MA) customers to have in-network access to Infirmary Health's hospitals, facilities and doctors.

Cigna Healthcare, Infirmary Health Reach Medicare Advantage Agreement

The headline numbers for Cigna (CI) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Cigna (CI) Reports Q3 Earnings: What Key Metrics Have to Say

The Cigna Group (NYSE:CI ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Ralph Giacobbe - Senior Vice President of Investor Relations David Cordani - Chairman and Chief Executive Officer Brian Evanko - Chief Financial Officer and President and Chief Executive Officer, Cigna Healthcare Eric Palmer - President and Chief Executive Officer, Evernorth Health Services Conference Call Participants AJ Rice - UBS Justin Lake - Wolfe Research Ryan Langston - TD Cowen Lisa Gill - JPMorgan Andrew Mok - Barclays Erin Wright - Morgan Stanley Scott Fidel - Stephens Adam Ron - Bank of America George Hill - Deutsche Bank Josh Raskin - Nephron Research Lance Wilkes - Bernstein Michael Ha - Baird Operator Ladies and gentlemen, thank you for standing by for the Cigna Group's Third Quarter 2024 Results Review. At this time all callers are in a listen-only mode.

The Cigna Group (CI) Q3 2024 Earnings Call Transcript

CI's strong third-quarter results benefit from a strong Evernorth Health Services segment. Higher expenses partially offset the positives.

Cigna Q3 Earnings Beat on Client Wins & Specialty Business Strength

On Thursday, Cigna Corporation CI reported third-quarter sales of $63.7 billion, up 30% year-over-year, beating the consensus of $59.35 billion.

Cigna's Q3 Profit Beats Street On Strong Demand For Pharmacy Benefit Management's Specialty Drugs, New Clients

Cigna (CI) came out with quarterly earnings of $7.51 per share, beating the Zacks Consensus Estimate of $7.22 per share. This compares to earnings of $6.77 per share a year ago.

Cigna (CI) Surpasses Q3 Earnings and Revenue Estimates

Cigna beat Wall Street estimates for third-quarter profit on Thursday, as its unit that runs the pharmacy benefit management business added new clients and saw strong demand for close copies of a blockbuster arthritis drug.

Cigna tops quarterly profit estimates on strength in pharmacy benefit management unit

Total revenues for the third quarter 2024 increased 30% to $63.7 billion Shareholders' net income for the third quarter 2024 was $0.7 billion, or $2.63 per share Adjusted income from operations1 for the third quarter 2024 was $2.1 billion, or $7.51 per share Reaffirms 2024 outlook2 for adjusted income from operations1,2 of at least $28.40 per share BLOOMFIELD, Conn. , Oct. 31, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE: CI) today reported strong third quarter 2024 results demonstrating focused execution across Evernorth Health Services and Cigna Healthcare.

The Cigna Group Reports Strong Third Quarter 2024 Results, Reaffirms 2024 Adjusted EPS Outlook

Natera

The Cigna Group reported a $739 million third quarter profit despite a $1 billion loss on its investment in clinic operator VillageMD.

Cigna Turns $739 Million Profit Despite $1 Billion Loss On VillageMD

Analysts expect the company to report earnings of $7.23 per share for the third quarter and sales of $59.6 billion.

Cigna Earnings Are Soon. It's Been a Bumpy Season for Managed Care Stocks.

CI's Q3 results are likely to be aided by strength in the specialty pharmacy business, partly offset by elevated medical costs resulting from higher utilization trends.

Will a Strong Evernorth Unit Benefit Cigna in Q3 Earnings?

There has been speculation of a massive merger in the medical sector between two massive health insurers. Specifically, the rumor is The Cigna Group NYSE: CI is interested in acquiring Humana Inc. NYSE: HUM.

Cigna Considers Humana Acquisition – What It Means for the Stocks

Get a deeper insight into the potential performance of Cigna (CI) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

News for Cigna Stock (CI)